Inhibition of acyl coenzyme a-cholesterol acyltransferase: A possible treatment of atherosclerosis?

摘要: Our full understanding of atherosclerosis and our ability to prevent its sequellae are incomplete. As a result, further investigation novel antiatherosclerotic mechanisms agents continues. Acyl coenzyme A-cholesterol acyltransferase (ACAT) inhibition has been evaluated as potential mechanism by which the current treatment arsenal may be expanded. ACAT is present in variety tissues responsible for catalyzing conversion free cholesterol more readily stored cholesteryl esters. Impressive lipid effects demonstrated animals have not generally human clinical trials. Partial with specific resulted lesion regression decreased progression, whereas complete via genetic alterations led an exacerbation deposition animal models. No inhibitor yet fully trials impact on atherosclerotic disease progression. Several hurdles, such sample size requirements needed detect effect over background therapy lack sensitive surrogate efficacy markers, served deterrent development this class investigational drug. However, recent technologic advancements, methods measuring progression available. Human currently underway, several reported Phase II Within next few years, results from these determine whether or inhibitors will added list options prevention